Jill Stewart
Psychiatric/Mental Health · Athens, GANPI 1629596093
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 266 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 15 manufacturers, the largest accounting for just 16.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,666 and has fallen 64.4% since, to $593 in 2025. Among psychiatric/mental health clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 266 payments — averaging $21.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$921
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$869
- Johnson & Johnson$692
- Lundbeck LLC$615
- Neurocrine Biosciences, Inc.$479
- Indivior Inc.$460
- plus $2K from 9 others
What the payments were for
- Food & beverage$5,50098%
- Education$942%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 43 | $921 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 46 | $869 |
| Johnson & Johnson | 29 | $692 |
| Lundbeck LLC | 33 | $615 |
| Neurocrine Biosciences, Inc. | 25 | $479 |
| Indivior Inc. | 18 | $460 |
| Teva Pharmaceuticals USA, Inc. | 30 | $396 |
| Supernus Pharmaceuticals, Inc. | 1 | $389 |
| Otsuka America Pharmaceutical, Inc. | 15 | $285 |
| AbbVie(2 entities) | 12 | $220 |
| Vanda Pharmaceuticals Inc. | 4 | $86 |
| E.r. Squibb & Sons, L.L.C. | 3 | $75 |
| Axsome Therapeutics, Inc. | 3 | $48 |
| Noven Therapeutics, LLC | 3 | $46 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$389
How this compares
$5,594 in reported general payments places this provider in the 95th percentile of 900 psychiatric/mental health providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 39 | $474,635 |
| Invega SustennaPaliperidone Palmitate | 91 | $319,832 |
| Invega HafyeraPaliperidone Palmitate | 13 | $204,675 |
| Abilify MaintenaAripiprazole | 47 | $129,206 |
| Invega TrinzaPaliperidone Palmitate | 16 | $111,914 |
| AristadaAripiprazole Lauroxil | 28 | $95,359 |
| IngrezzaValbenazine Tosylate | 12 | $89,874 |
| RexultiBrexpiprazole | 37 | $68,601 |
| VraylarCariprazine Hcl | 43 | $68,317 |
| FanaptIloperidone | 24 | $35,514 |
| TrintellixVortioxetine Hydrobromide | 54 | $27,380 |
| LatudaLurasidone Hcl | 16 | $23,316 |
| VivitrolNaltrexone Microspheres | 13 | $20,126 |
| Paliperidone ErPaliperidone | 62 | $16,434 |
| AuvelityDextromethorphan Hbr/Bupropion | 13 | $14,053 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $396 | $474,63539 claims |
| Johnson & JohnsonInvega Sustenna, Invega Trinza | $692 | $431,746107 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $285 | $197,80784 claims |
| Alkermes, Inc.Aristada, Vivitrol | $921 | $115,48541 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $479 | $89,87412 claims |
| AbbVieVraylar | $220 | $68,31743 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $86 | $35,51424 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $13 | $27,38054 claims |
| Axsome Therapeutics, Inc.Auvelity | $48 | $14,05313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 900 psychiatric/mental health providers in Georgia.
Other psychiatric/mental health in Athens
- Obianuju OkpalaAthens$5K
- Phyillis Kennedy-HowellBarney$673K
- Jessica OliverThomasville$233K
- Sherri KrollBrunswick$155K
- Taylor LeblancAlbany$48K
- Greta HeckmannDalton$28K
- Matthew DowdyWoodstock$25K
- Natasha GilesLoganville$21K
- Darrick SealeyWarner Robins$17K
- Olufunke AdewunmiSmyrna$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.